COMMUNIQUÉS West-GlobeNewswire

Collegium Announces $25 Million Accelerated Share Repurchase Program
12/05/2025
STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical [...]
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
12/05/2025
Conference call will be held today, Monday, May 12 at 9:00 am ET CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company [...]
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP
12/05/2025
May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019 Company nears [...]
NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor
12/05/2025
Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies EDEN PRAIRIE, Minn., May 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: [...]
ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer and Member of the Board of Directors
12/05/2025
Industry veteran brings over 30 years of experience driving technical, operational, and commercial excellence Has served as ElevateBio’s strategic advisor over the past year, working closely with the executive team to [...]
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
12/05/2025
Adds nine additional countries to the Company’s ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) [...]
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025
12/05/2025
Conference Call Scheduled for Thursday, May 15, 2025 at 9:00 AM ET PORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company [...]
Transactions in Connection with Share Buy-back Program
12/05/2025
Company Announcement COPENHAGEN, Denmark; May 12, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital [...]
Brain Cancer Canada Grants McGill University $100,000 to Advance Pediatric Brain Cancer Research
12/05/2025
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is pleased to award a $100,000 pediatric research grant to Dr. Carl Ernst, professor and scientist at McGill University, and his team. The work explores a [...]
Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
12/05/2025
BOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced the successful [...]
Porch Light Health Acquires Comprehensive Behavioral Health Center to Expand Access to Full-Spectrum Addiction Treatment
12/05/2025
DENVER, May 12, 2025 (GLOBE NEWSWIRE) -- Porch Light Health, the largest addiction medicine practice in Colorado, offering outpatient Medications for Addiction Treatment (MAT) at more than 60 treatment locations, is [...]
InBrain Pharma Secures €1.8 Million in Funding for the PERCEPAR Project under France 2030’s “First Factory” Initiative to Industrialize Anaerobic Dopamine Production for Parkinson’s Disease
12/05/2025
InBrain Pharma Secures €1.8 Million in Funding for the PERCEPAR Project under France 2030’s “First Factory” Initiative to Industrialize Anaerobic Dopamine Production for Parkinson’s Disease Lille, May 12, 2025 – InBrain [...]
CONVOCATION À L’ASSEMBLÉE GÉNÉRALE ORDINAIRE 2025 D’IBA SA
12/05/2025
- MERCREDI 11 JUIN 2025 À 10H00 - Cher Actionnaire, Nous avons l’honneur de vous convoquer à l’Assemblée Générale Ordinaire (l’« AGO » ) des actionnaires d’IBA qui se tiendra le mercredi 11 juin 2025 à 10h00 , pour [...]
CONVENING NOTICE TO THE ORDINARY GENERAL MEETING 2025 OF IBA SA
12/05/2025
– WEDNESDAY, JUNE 11, 2025, AT 10:00 A.M. – Dear Shareholder, We have the honor of convening you to the Ordinary General Meeting (the " OGM ") of IBA to be held on Wednesday June 11, 2025 at 10:00 A.M., to deliberate on [...]
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
12/05/2025
Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53% APG808 demonstrated [...]
Q1 2025 Qualitative Update: Tecan reports performance in line with expectations and confirms outlook for full year 2025
12/05/2025
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q1 2025 Qualitative Update: Tecan reports performance in line with expectations and confirms outlook for full year 2025 Männedorf, [...]
Valneva fait un point sur les recommandations d’utilisation d'IXCHIQ® chez les personnes âgées aux États-Unis
12/05/2025
Saint Herblain (France), le 12 mai 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence de santé américaine Food and Drug Administration (FDA [...]
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
12/05/2025
Saint Herblain (France), May, 12 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control [...]
Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025
12/05/2025
Press release – No. 8 / 2025 Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 Copenhagen, Denmark, May 12, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a [...]

Pages